MapPharma posts
FeedPosted Feb 17th 2009 10:55AM by Laurie Pasternack (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Google (GOOG), Daimler (DAI), Marriott Intl'A' (MAR), Analyst Initiations, Lloyds TSB Group plc ADS (LYG), Suntech Power Hldgs ADS (STP), China Mobile Limited (CHL)
Analyst upgrades:
- Baird upgraded Starwood Hotels (NYSE: HOT), Host Hotels (NYSE: HST) and Marriott (NYSE: MAR) to Outperform from Neutral based on valuation and indications that negative sentiment has reached a bottom.
- Citigroup upgraded Torchmark (NYSE: TMK) to Buy from Hold as they find the valuation attractive and think management can grow earnings and book value in 2009/2010. Despite upgrading, the firm lowered their target price to $37 from $45.
- ASM International (NASDAQ: ASMI) was added to Goldman's Conviction Buy List.
- Credit Suisse (NYSE: CS) was raised to Overweight from Equal Weight at Morgan Stanley.
- Live Nation (NYSE: LYV) was upgraded at Natixis to Buy from Hold.
Continue reading Analyst upgrades, downgrades and initiations: HOT, GOOG, WPI, LYG ...
Posted Nov 14th 2007 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Coca-Cola (KO), PepsiCo (PEP), Carnival Corp (CCL), Alcatel-LucentADS (ALU), Analyst Initiations
MOST NOTEWORTHY: Atmel, Skyworks, Alcatel-Lucent, Parexel and Map Pharma were today's noteworthy initiations:
- Kaufman Bros. initiated Atmel (NASDAQ: ATML) with a Buy rating and $6 target, as they believe the company's increasing focus around its core microcontroller business can drive an improved growth and profitability profile going forward and would be buyers at current levels.
- The firm also started shares of Skyworks (NASDAQ: SWKS) with a Buy rating and a $10 target, as they like the company's balanced customer positioning and find the stock attractively valued at current levels.
- JP Morgan initiated Alcatel-Lucent (NYSE: ALU) with an Overweight rating and believes the risks are more than fully priced into shares at current levels.
- Parexel (NADSAQ: PRXL) was initiated with a Neutral rating at Broadpoint, as they believe the company's improved execution is already priced into shares.
- Deutsche Bank finds shares of Map Pharmaceuticals (NASDAQ: MAPP) attractively valued given the opportunity from the company's two late stage product candidates, UDB and Tempo Migraine. The firm started shares off with a Buy rating and $19 target.
OTHER INITIATIONS: